Oncotarget sponsors 19th International p53 Workshop in Italy
2024-04-29
(Press-News.org)
Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024.
BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.
“Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently mutated gene in cancer, will take center stage at the 19th International p53 Workshop.” – ICGEB.org
Among the 24 invited speakers at the 19th International p53 Workshop, 18 speakers have published new research on p53 in Oncotarget. These distinguished speakers who have published with Oncotarget include Dr. Andrei Gudkov — one of Oncotarget’s founding Editors-in-Chief. Dr. Gudkov will be speaking in the session on “p53 Inflammation and Immunity” and moderating the session on “Targeting p53 in Human Disease.”
“The event will gather leading scientists, clinicians, and researchers from around the world providing a unique opportunity to delve into the latest discoveries and innovations related to TP53 biology and explore the intricate role of TP53 in cancer and its potential for transformative impact in oncology.” – ICGEB.org
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X, formerly Twitter
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Reddit
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Oncotarget Journal Office
6666 East Quaker Street., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-04-29
ITHACA, N.Y. -- New York state solar construction workers – whose numbers are expected to grow rapidly to meet climate goals – are transient, may not receive benefits and are subject to racial disparities in pay, finds a new report from the Climate Jobs Institute (CJI) at Cornell University.
“Exploring the Conditions of the New York Solar Workforce” was funded by the New York State Department of Labor and surveyed more than 260 solar installation and maintenance workers. The exploratory study is the first to focus on workers’ experiences, seeking to bridge gaps in government and industry ...
2024-04-29
The fragile qubits that make up quantum computers offer a powerful computational tool, yet also present a conundrum: How can engineers create practical, workable quantum systems out of bits that are so easily disturbed — and wiped of data — by tiny changes in their environment?
Engineers have long struggled with how to make quantum computers less error-prone, often by developing ways to detect and correct errors rather than prevent them in the first place. However, many such error-correction schemes involve duplicating information across hundreds or thousands of physical qubits at once, which quickly becomes hard to scale up in an efficient way.
Now, ...
2024-04-29
New research using live SARS-CoV-2 virus reveals an updated vaccine provides a strong immune response against previous strains and emerging variants.
The findings by researchers at Oregon Health & Science University, published in the journal Emerging Infectious Diseases, suggest a clear benefit in receiving updated vaccinations on a regular basis, especially among older people or those with underlying medical conditions.
“The virus is still circulating, it’s continuing to evolve, and it remains dangerous,” said co-senior author Fikadu Tafesse, Ph.D., associate professor of molecular ...
2024-04-29
Dr Carl Senior identified two types of smile – affiliative and reward – given by political leaders during the last UK general election in 2019
The eventual winner, Boris Johnson, was found to display the affiliative smile, which acts to align voter behaviour
The study is the first to look at how supporters of election losers react to the eventual winner.
New research led by Aston University’s Dr Carl Senior has found that the type of smile used by a political leader can influence voters to support them and their political agenda.
There are many different types of smile, and the ...
2024-04-29
Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the German Center for Infection Research (DZIF) have discovered a new so-called lantibiotic, namely epilancin A37. It is produced by staphylococci that colonize the skin and acts specifically against their main competitors there, the corynebacteria. This specificity is presumably mediated by a very special mechanism of action, which the researchers were able to decipher in detail. ...
2024-04-29
Quantitative study assesses how gender and race impact young athletes’ perceptions of their coaches
Across the U.S., there are over 8 million student-athletes in high school and college. Engaging in sports can contribute to physical, mental, and social benefits, and coaches can play a key role in student-athletes’ continued participation in sports.
A recent study led by UNC Greensboro’s Dr. Tsz Lun (Alan) Chu, published in Sport, Exercise, and Performance Psychology, examines how multiple aspects of a young athlete’s ...
2024-04-29
The quest to develop universal donor blood has taken a decisive step forward. Researchers at DTU and Lund University have discovered enzymes that, when mixed with red blood cells, are able to remove specific sugars that make up the A and B antigens in the human ABO blood groups. The results have been published in the scientific journal Nature Microbiology.
"For the first time, the new enzyme cocktails not only remove the well-described A and B antigens, but also extended variants previously not recognized as problematic for transfusion safety. We are close to being able to produce universal blood from group B donors, while there is still work to be done to convert ...
2024-04-29
It is estimated that up to 85% of stars exist in binary star systems, some even in systems with three or more stars. These stellar pairs are born together out of the same molecular cloud from a shared abundance of chemical building blocks, so astronomers would expect to find that they have nearly identical compositions and planetary systems. However, for many binaries that isn’t the case. While some proposed explanations attribute these dissimilarities to events occurring after the stars evolved, a team of astronomers have confirmed for the first time that they can actually originate ...
2024-04-29
Researcher Ko Mochizuki of the University of Tokyo discovered that two species in the genus Angelica are pollinated primarily by hornets. This overturns the conventional belief that Angelica species are “generalists,” meaning that there is not one primary pollinator but a variety of species. As hornets are rarely primary pollinators, the discovery also impacts future ecological research and conservation efforts. The findings were published in the journal Ecology.
White, small, open, secretes nectar and produces pollen: these are the kinds of flowers that many types of insects can reach ...
2024-04-29
About The Study: In this randomized, placebo-controlled clinical trial that included 3,020 patients with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.
Authors: Wendy Y. Chen, M.D., of the Dana Farber Cancer Institute in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media ...
LAST 30 PRESS RELEASES:
[Press-News.org] Oncotarget sponsors 19th International p53 Workshop in Italy
